Based on the theory that ATRA therapy is ineffective in non-APL AML due to a block in the transcriptional activation of retinoic acid receptor target genes, researchers tested the hypothesis that treatment with a LSD1 inhibitor could “unlock” ATRA’s effect. Here, KDM1A is linked to acute myeloid leukemia.